Clinical Trials Logo

Healthy clinical trials

View clinical trials related to Healthy.

Filter by:

NCT ID: NCT04619875 Completed - Healthy Clinical Trials

A Clinical Study to Assess the Effect of Increasing Intake Amounts of Two Novel Glycans on the Gut Microbiota of Healthy Subjects

Start date: September 11, 2017
Phase: N/A
Study type: Interventional

This exploratory, randomized, open label study aims to explore the safety, tolerability, pharmacokinetics, and effects of increasing intake amounts of two novel glycans on the gut microbiota of healthy subjects.

NCT ID: NCT04619251 Completed - Healthy Clinical Trials

A Study in Healthy Japanese Men to Test How Different Doses of BI 1323495 Are Tolerated and How Itraconazole Influences the Amount of BI 1323495 in the Blood

Start date: November 13, 2020
Phase: Phase 1
Study type: Interventional

The main objective of the single-rising dose (SRD) part and the multiple rising dose (MD) part is to investigate safety, tolerability, pharmacokinetics and pharmacodynamics (for MD part only) following single rising doses and multiple oral doses of BI 1323495 in healthy male Japanese subjects genotyped as poor metabolizers (PM) and extensive metabolizers (EM) of UGT2B17. The main objective of the drug-drug interaction (DDI) part is to investigate the relative bioavailability of a single oral dose of BI 1323495 when given alone (treatment R) or in combination with itraconazole (treatment T) in healthy male subjects genotyped as PM of UGT2B17.

NCT ID: NCT04618302 Completed - Healthy Clinical Trials

Lung Diffusing Capacity for Nitric Oxide During Cycling Exercise

Start date: October 19, 2020
Phase:
Study type: Observational

This study investigates the test-retest reliability of the lung diffusing capacity for nitric oxide in healthy individuals during exercise.

NCT ID: NCT04617691 Completed - Healthy Clinical Trials

A Study of Intravenous Formulation of Guselkumab Using Prefilled Syringes and Final Vialed Product in Healthy Participants

Start date: November 30, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the bioequivalence of an intravenous (IV) administration of the guselkumab formulation using UltraSafe Plus Passive Needle Guard (PFS-U) to create the IV solution versus the guselkumab formulation using Final Vialed Product (FVP) (IV) to create the IV solution.

NCT ID: NCT04616027 Completed - Healthy Clinical Trials

STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT

Start date: January 13, 2021
Phase: Phase 1
Study type: Interventional

This study will characterize the effect of varying degrees of renal impairment on the pharmacokinetics (PK), safety and tolerability of a single oral dose of PF- 06882961 compared with participants with normal renal function.

NCT ID: NCT04612517 Completed - Healthy Clinical Trials

A Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

Start date: October 26, 2020
Phase: Early Phase 1
Study type: Interventional

This is a randomised, double-blind, placebo-controlled, multiple ascending dose trial in healthy subjects, randomised to ZP7570 or placebo within each cohort

NCT ID: NCT04612400 Completed - Healthy Clinical Trials

Whole Body Protein Metabolism of a Whey/EAA Supplement Using Continuous Oral Stable Isotopes

Start date: November 4, 2020
Phase: N/A
Study type: Interventional

To evaluate the validity of a continuous oral sip-feeding method of stable isotope tracer for the evaluation of whole-body protein metabolism in response to two different doses of an EAA/whey protein supplement (Low=6.3g and High=12.6g). Results will be compared to those previously determined by constant infusion with the same EAA/whey supplement.

NCT ID: NCT04611971 Completed - Healthy Clinical Trials

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 2

Start date: October 27, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to characterize the delayed-type hypersensitivity (DTH) response at the site of Candin intradermal injection in the presence of a targeted immune pathway inhibitor.

NCT ID: NCT04611789 Completed - Healthy Clinical Trials

A Study of LY3832479 (LY-CoV016) in Healthy Participants 1

Start date: November 2, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety and tolerability of LY3832479 when it is given by injection just under the skin to healthy participants. Blood tests will be done to check how much LY3832479 is in the bloodstream and how long the body takes to eliminate it. Participation could last up to 16 weeks and may include up to six visits to the study center, with a one-week overnight stay.

NCT ID: NCT04610580 Completed - Healthy Clinical Trials

Bioavailability Study of 2 Oral Formulations of ALXN1840

Start date: January 31, 2021
Phase: Phase 1
Study type: Interventional

The study will assess the relative bioavailability of 2 different formulations of ALXN1840 in healthy participants.